Key Takeaway
Semax is a synthetic fragment of ACTH (4-10) that upregulates BDNF, modulates dopamine and serotonin, and has been approved in Russia since 2011 for cognitive disorders. Users report improved focus, mental clarity, and reduced brain fog. However, there are no Western randomized controlled trials for ADHD, and all clinical data comes from Russian research. Semax is currently on the FDA's Category 2 list in the US, though reclassification is expected. Semax is ranked in our 8 Best Peptides for Brain Function & Cognitive Enhancement guide. Check semax status in our FDA peptide ban article.
The search for non-stimulant cognitive support has pushed peptides into the conversation. Semax, a seven-amino-acid peptide developed at the Institute of Molecular Genetics in Moscow, is one of the most discussed options. It has been used clinically in Russia for over a decade, and online communities are full of reports from people using it for focus, memory, and ADHD symptom management.
The interest is understandable. Stimulant medications for ADHD work well but come with side effects that some people find hard to tolerate: appetite suppression, insomnia, anxiety, cardiovascular strain, and the risk of dependence. A peptide that improves focus through a completely different mechanism, without stimulant side effects, would be a significant option. The question is whether the evidence supports that promise. For anxiety-dominant profiles, see our 5 Best Peptides for Anxiety: Selank, Semax, DSIP & Oxytocin guide.
What Is Semax and How Does It Work?
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analogue of the ACTH (4-10) fragment, which is a portion of adrenocorticotropic hormone. Despite being derived from a stress hormone fragment, Semax does not stimulate the adrenal glands or increase cortisol production. Its effects are primarily neurological.1
Semax works through several mechanisms that are relevant to attention and cognition:
BDNF upregulation. This is the most studied mechanism. A single application of Semax produces a 1.4-fold increase in brain-derived neurotrophic factor (BDNF) protein levels in the hippocampus, along with a 1.6-fold increase in TrkB tyrosine phosphorylation (the receptor BDNF acts through). mRNA expression increases even more: a 3-fold increase in exon III BDNF mRNA and a 2-fold increase in TrkB mRNA.2
BDNF is sometimes called "fertilizer for the brain." It supports neuronal survival, promotes the growth of new synaptic connections, and plays a role in learning and memory consolidation. Low BDNF levels have been found in ADHD populations, depression, and age-related cognitive decline.3
Dopamine and serotonin modulation. Semax activates serotonergic and dopaminergic brain systems. Unlike stimulant medications that primarily increase dopamine availability through reuptake inhibition (Ritalin) or increased release (Adderall), Semax appears to modulate these systems more gently. The dopaminergic effects are relevant to ADHD because dopamine deficiency in the prefrontal cortex is a core feature of the condition.
Nerve growth factor (NGF) effects. Semax increases NGF expression, which supports cholinergic neurons involved in attention and memory. This provides another pathway through which the peptide could affect cognitive function.
What Is Semax Approved for in Russia?
Semax was added to the Russian List of Vital and Essential Drugs on December 7, 2011. It is prescribed in Russia for:4
- Stroke recovery and transient ischemic attack
- Memory and cognitive disorders
- Peptic ulcer disease
- Optic nerve disease
- Immune system support
The Russian clinical data includes studies on stroke recovery where Semax improved neurological outcomes, and cognitive disorder trials where it improved memory test performance. In one study, participants who received Semax demonstrated a 71% accuracy rate on a memory test compared to 41% in the control group, following a single intranasal dose of 16 mcg/kg.5
The limitation with all of this data is that most studies were published in Russian-language journals, many used small sample sizes, and none meet the standards of a large Western randomized controlled trial. The Alzheimer's Drug Discovery Foundation reviewed the available evidence and noted that while the mechanistic data is promising, the clinical evidence remains preliminary.
What Do Users Report for Focus and ADHD Symptoms?
Anecdotal reports from Semax users consistently describe the following effects:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Improved focus and concentration. Users report being able to sustain attention on tasks for longer periods without the "jittery" quality of stimulants.
- Reduced brain fog. Many describe a sense of mental clarity, particularly in the first few hours after intranasal administration.
- Better verbal fluency. Some users report that words come more easily and conversation feels more natural.
- Subtle mood improvement. Likely related to serotonin modulation, some users describe a mild anxiolytic effect.
- No crash. Unlike stimulant medications, users generally report no rebound fatigue or mood drop as the effects wear off.
These reports should be taken for what they are: subjective experiences without controlled conditions. Placebo effects are significant in cognitive enhancement, and self-selection bias is strong in online communities. But the consistency of reports across thousands of users, combined with the mechanistic plausibility, suggests real effects.
How Does Semax Compare to Traditional ADHD Medications?
Comparing Semax to established ADHD medications requires honesty about the asymmetry in evidence. Adderall and Ritalin have decades of randomized controlled trials behind them. Semax has mechanistic studies, Russian clinical data, and user reports. They are not on equal footing scientifically.
| Feature | Semax | Adderall (Amphetamine) | Ritalin (Methylphenidate) |
|---|---|---|---|
| Mechanism | BDNF upregulation, dopamine/serotonin modulation | Increased dopamine/norepinephrine release | Dopamine/norepinephrine reuptake inhibition |
| Administration | Intranasal spray | Oral | Oral |
| Onset | 30-60 minutes | 30-60 minutes | 20-30 minutes |
| Duration | Up to 24 hours (per study) | 4-6 hours (IR), 8-12 hours (XR) | 3-4 hours (IR), 6-8 hours (XR) |
| Appetite suppression | Not reported | Common | Common |
| Insomnia risk | Low | Moderate to high | Moderate |
| Dependence potential | None reported | Schedule II controlled substance | Schedule II controlled substance |
| Western RCT evidence | None | Extensive | Extensive |
| FDA status (US) | Category 2 (restricted) | FDA-approved | FDA-approved |
The honest summary: Semax has a favorable side effect profile and a plausible mechanism for improving focus. But it has not been tested in the rigorous way that would be needed to recommend it as an ADHD treatment. It is not a proven replacement for stimulant medications. It may be a useful adjunct or alternative for people who cannot tolerate stimulants, but that decision should be made with a prescriber who understands the limitations of the evidence.
What Is the Typical Dosing Protocol for Semax?
Semax is administered intranasally because it has poor oral bioavailability (like most peptides, stomach acid destroys it). The nasal mucosa provides rapid absorption into the bloodstream and relatively direct access to the central nervous system.6
Typical dosing ranges reported in clinical use and user communities:
- Standard dose: 200-600 mcg per day, divided into 1-3 administrations
- Research dose (from Russian studies): 16-50 mcg/kg body weight per day
- Common starting dose: 200 mcg once daily, typically in the morning
- Duration of use: Most protocols suggest cycles of 10-20 days, followed by a break of equal length
Effects are typically noticed within 30-60 minutes of intranasal administration. Based on the limited pharmacokinetic data available, a single dose at 16 mcg/kg appears to produce effects lasting up to 24 hours.
An enhanced version called N-Acetyl Semax (NASA) has also gained attention. This modified form adds an acetyl group that may improve stability and potency, though even less clinical data exists for this variant.
What Are the Side Effects of Semax?
Based on Russian clinical data and user reports, Semax has a mild side effect profile:
- Nasal irritation or dryness (most common, related to the delivery method)
- Mild headache (occasional, typically at higher doses)
- Temporary increase in anxiety (rare, more common with higher doses)
- Slight increase in blood pressure (transient, not clinically significant in most reports)
No serious adverse events have been reported in the published literature. There are no reports of dependence, withdrawal, or tolerance development. The safety profile compares favorably to stimulant medications, though this comparison is limited by the smaller body of evidence for Semax.
What Is the Current Legal Status of Semax in the US?
Semax is currently on the FDA's Category 2 list, which means it cannot be legally compounded by 503A pharmacies in the United States. It was one of the 19 peptides placed in Category 2 in September 2023.7
In February 2026, HHS Secretary RFK Jr. announced plans to reclassify 14 Category 2 peptides back to Category 1, and Semax is on that list. If the reclassification is formalized, compounding pharmacies would again be able to prepare Semax under physician prescription. No formal FDA rule change has been published as of April 2026.
For a full breakdown of the current peptide regulatory situation, see our FDA peptide ban 2026 guide.
The Bottom Line: Can Semax Replace Stimulants?
Not based on current evidence. Semax has a compelling mechanism of action, a good safety profile, and consistent user reports of cognitive benefits. But "replace" implies equivalence, and the evidence is not there. No Western RCT has tested Semax against placebo for ADHD. No head-to-head trial has compared it to Adderall or Ritalin.
What Semax might be, once legal compounding resumes, is an option for patients who want non-stimulant cognitive support. It could be appropriate for people with mild focus difficulties who do not meet full ADHD diagnostic criteria, or for those who cannot tolerate stimulant side effects and want to try a different approach under physician supervision.
Anyone considering Semax for ADHD should have a proper diagnostic evaluation first. ADHD is a real neurodevelopmental condition, and treating it with an unproven peptide instead of established medications carries risk, particularly the risk of under-treatment.
Frequently Asked Questions
Is Semax FDA-approved?
No. Semax has not been evaluated or approved by the FDA. It is approved in Russia, where it has been on the List of Vital and Essential Drugs since 2011. In the US, it is currently on the FDA's Category 2 list, which restricts it from compounding pharmacies. Reclassification to Category 1 has been announced but not yet formalized.
How does Semax differ from Adderall?
Adderall works primarily by increasing dopamine and norepinephrine release in the brain. Semax works by upregulating BDNF, modulating dopamine and serotonin systems, and promoting nerve growth factor. Adderall is a Schedule II controlled substance with significant side effects and dependence potential. Semax has no reported dependence risk but also lacks Western clinical trial evidence.
What is the recommended dose of Semax?
Typical intranasal doses range from 200 to 600 mcg per day. Russian clinical protocols use weight-based dosing of 16-50 mcg/kg per day. Most users start with 200 mcg once daily in the morning. Cycling protocols of 10-20 days on, followed by an equal break, are commonly reported.
Does Semax have side effects?
Reported side effects are mild: nasal irritation, occasional headache, rare anxiety at higher doses, and transient blood pressure increases. No serious adverse events, dependence, or withdrawal have been reported in the published literature. The side effect profile is considerably milder than stimulant ADHD medications.
Can I buy Semax in the United States?
As of April 2026, Semax is on the FDA's Category 2 list and cannot be legally compounded by US pharmacies. Some vendors sell it as a "research chemical," but these products are not approved for human use and carry unknown quality risks. Legal compounding access may resume if the announced reclassification is formalized.
What is the difference between Semax and N-Acetyl Semax?
N-Acetyl Semax (sometimes called NASA) is a modified version with an acetyl group added to the N-terminus. This modification may improve stability and potency. Some users report stronger effects from the acetylated version. Even less clinical data exists for N-Acetyl Semax than for standard Semax.
How long does Semax take to work?
Noticeable cognitive effects are typically reported within 30-60 minutes of intranasal administration. Based on pharmacokinetic data, effects from a single dose at 16 mcg/kg may last up to 24 hours. Some users report cumulative benefits over several days of use.
Is Semax safe to use with other medications?
Limited drug interaction data is available. Russian prescribing information does not list major contraindications, but the absence of interaction studies in Western medicine means caution is warranted. Do not combine Semax with other cognitive-enhancing medications without physician guidance, and always disclose all supplements and medications to your prescriber.
Medical References
- Dolotov OV, et al. "Semax, an analogue of adrenocorticotropin (4-10), is a modulator of the immune response." Regulatory Peptides. 2006. PubMed 16996699
- Dolotov OV, et al. "Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus." Brain Research. 2006. PubMed 16996037
- Dolotov OV, et al. "Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain." Journal of Neurochemistry. 2006. PubMed 16635254
- "Semax." Wikipedia. wikipedia.org
- "Semax: Cognitive Vitality For Researchers." Alzheimer's Drug Discovery Foundation. alzdiscovery.org
- "Semax: A Neuroprotection and Cognitive Enhancement Peptide." PeptideFox. peptidefox.com
- "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." U.S. Food and Drug Administration. fda.gov
This article is for educational purposes only and does not constitute medical advice. Semax is not FDA-approved and is currently restricted from compounding in the United States. ADHD is a medical condition that requires professional evaluation and treatment. Do not discontinue prescribed medications without consulting your physician. FormBlends does not currently prescribe Semax.
Reviewed by the FormBlends Medical Team. Last updated: 2026-04-10
Author: FormBlends Medical Team